Dr John Stageman
Appointed December 2008
Dr Stageman was responsible for developing AstraZeneca’s
competitive biopharmaceutical strategy, leading to the acquisition
of Cambridge Antibody Technology and of MedImmune. After a period
in a transitional role as General Manager of Cambridge, John has
recently returned to the North West as Vice President of UK Science
Affairs. He has been a member of the North West Science Council
since its inception in 2002, and a member of the Biotechnology and
Biological Sciences Research Council since May 2008, and is an
Honorary Professor in Life Sciences at the University of
Manchester.
He holds no other ministerial appointments.
Board sub-committee involvement:
- Member of the Enterprise & Skills Sub Committee
- Member of the Audit Committee
- Member of the Equality and Diversity Sub Committee
- Member of the European Sub Committee
Register of Interests - updated 20th January
2010
| Company Name |
Nature of Interest |
Direct or Indirect Interest |
| Astra Zeneca |
Employee |
Direct |
| Daresbury Executive Steering Group |
Advisor |
Direct |
| Manchester Premier Fund (managed by MTI) |
Member of Advisory Board |
Direct |
| MIMIT |
Chairman of Board |
Indirect |
| North West Equity Fund AZ Ltd |
Partner Representative |
Direct |